Skip to main content
Equibles

Blair Jackson

COO

Alkermes plc. (ALKS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Alkermes plc. publishes a filing, an earnings call transcript or a press release.

Get ALKS alerts

About Blair Jackson

Blair Jackson is recorded as COO at Alkermes plc. (ALKS). The proxy statement of Alkermes plc. reports total compensation of $4,030,905 for Blair Jackson in fiscal 2025, including a base salary of $736,450. Disclosed compensation is on record for 5 fiscal years. Blair Jackson has spoken on 9 earnings calls and 2 other investor events across 1 company, most recently for Alkermes plc. on June 10, 2026. Alkermes plc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Alkermes plc. includes Blair C. Jackson (CEO, CFO and COO), Mr. Richard F. Pops (CEO), Iain M. Brown (CFO and Chief Accounting Officer) and 7 others.

Blair Jackson on recent calls

“Yeah, I think if you look over the last year, we've really been looking to widen our portfolio and our pipeline and our ex-neganism and really laying down a number of different bets over the next little while and programs that are going to report out over the next 12 months.”
COO, Goldman Sachs 47th Annual Global Healthcare Conference ·
“Yeah, I think if you look over the last year, we've really been looking to widen our portfolio and our pipeline and our ex-neganism and really laying down a number of different bets over the next little while and programs that are going to report out over the next 12 months.”
COO, Goldman Sachs 47th Annual Global Healthcare Conference ·
“As we outlined earlier in January, this year we are expanding our erexin development programs into disease areas outside of sleep medicine. We are doing so with two new molecules from our portfolio, ELX 7290 and ELX 4510.”
COO, Alkermes plc. Q1 FY2026 Earnings Call ·
“So actually, valoxabate is a really interesting asset that came over as part of the Avidel transaction. It has an opportunity to play in really the low to no sodium space.”
COO, Alkermes plc. Q4 FY2025 Earnings Call ·
“Our second quarter financial results were strong and reflected solid commercial and operational execution. We had planned for accelerated growth from the first quarter, and we exceeded our expectations.”
COO, Alkermes plc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Alkermes plc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Alkermes plc. (ALKS) $736,450 $4,030,905
2024 Alkermes plc. (ALKS) $715,000 $4,891,034
2023 Alkermes plc. (ALKS) $650,000 $4,561,915
2022 Alkermes plc. (ALKS) $600,000 $4,470,120
2021 Alkermes plc. (ALKS) $540,000 $3,769,824

Recent activity